title: MDCK cell-cultured influenza virus vaccine protects mice from lethal challenge with different influenza viruses.
abstract: Influenza epidemics are major health concern worldwide. Vaccination is the major strategy to protect the general population from a pandemic. Currently, most influenza vaccines are manufactured using chicken embroynated eggs, but this manufacturing method has potential limitations, and cell-based vaccines offer a number of advantages over the traditional method. We reported here using the scalable bioreactor to produce pandemic influenza virus vaccine in a Madin-Darby canine kidney cell culture system. In the 7.5-L bioreactor, the cell concentration reached to 3.2 × 10(6) cells/mL and the highest virus titers of 256 HAU/50 μL and 1 × 10(7) TCID50/mL. The HA concentration was found to be 11.2 μg/mL. The vaccines produced by the cell-cultured system induced neutralization antibodies, cross-reactive T-cell responses, and were protective in a mouse model against different lethal influenza virus challenge. These data indicate that microcarrier-based cell-cultured influenza virus vaccine manufacture system in scalable bioreactor could be used to produce effective pandemic influenza virus vaccines.
authors.affiliation: Department of Immunology, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.
authors.forename: Kun
authors.initials: K
authors.lastname: Liu
authors.forename: Zhidong
authors.initials: Z
authors.lastname: Yao
authors.forename: Liangyan
authors.initials: L
authors.lastname: Zhang
authors.forename: Junli
authors.initials: J
authors.lastname: Li
authors.forename: Li
authors.initials: L
authors.lastname: Xing
authors.forename: Xiliang
authors.initials: X
authors.lastname: Wang
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D019149:Bioreactors; D001709:Biotechnology / Q000379:methods; D018929:Cell Culture Techniques; D002460:Cell Line; D056738:Cross Protection; D004195:Disease Models, Animal; D004285:Dogs; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*; D051379:Mice; D009975:Orthomyxoviridae / Q000276:immunology* / Q000472:pathogenicity; D009976:Orthomyxoviridae Infections / Q000517:prevention & control*; D016019:Survival Analysis; D013601:T-Lymphocytes / Q000276:immunology; D013678:Technology, Pharmaceutical / Q000379:methods; D019562:Viral Load
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D007252:Influenza Vaccines